Literature DB >> 10343196

Clinical significance of c-met oncogene alterations in human colorectal cancer.

K Umeki1, G Shiota, H Kawasaki.   

Abstract

Abnormalities of the c-met oncogene have been studied in cancers of many organs including thyroid, lung, pancreas, and stomach. However, little is known about the clinical significance of c-met oncogene abnormalities in colorectal cancer. We investigated the amplification and overexpression of the c-met gene in surgically resected samples from 43 patients with colorectal cancer using Southern blot analysis and reverse transcription-polymerase chain reaction (RT-PCR). Four of 33 (12%) samples of colorectal cancer showed amplification of the c-met gene. Twelve of 43 (30%) exhibited overexpression of the c-met gene. The patients with c-met overexpression showed greater tumor size, compared to those without c-met overexpression (p < 0.05). However, there were no differences in clinical stage, histological differentiation, tumor markers, or overall survival between two groups. The findings of the present study suggest that overexpression of c-met gene plays an important role in growth of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10343196     DOI: 10.1159/000011985

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  19 in total

Review 1.  High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.

Authors:  HeLi Gao; Mei Guan; Zhao Sun; ChunMei Bai
Journal:  Tumour Biol       Date:  2015-01-31

Review 2.  Prognostic value of c-Met in colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Xiao-Feng Yu; Jian Zou; Zi-Hua Luo
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 3.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

4.  Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis.

Authors:  K Fazekas; O Csuka; I Köves; E Rásó; J Tímár
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.

Authors:  Tong-Chao Liu; Xia Peng; Yu-Chi Ma; Yin-Chun Ji; Dan-Qi Chen; Ming-Yue Zheng; Dong-Mei Zhao; Mao-Sheng Cheng; Mei-Yu Geng; Jing-Kang Shen; Jing Ai; Bing Xiong
Journal:  Acta Pharmacol Sin       Date:  2016-04-04       Impact factor: 6.150

Review 6.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

Review 7.  C-MET as a new therapeutic target for the development of novel anticancer drugs.

Authors:  I Cañadas; F Rojo; M Arumí-Uría; A Rovira; J Albanell; E Arriola
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

8.  Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.

Authors:  Shahab Uddin; Azhar R Hussain; Maqbool Ahmed; Nasser Al-Sanea; Alaa Abduljabbar; Luai H Ashari; Samar Alhomoud; Fouad Al-Dayel; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Am J Pathol       Date:  2011-10-05       Impact factor: 4.307

9.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

10.  Targeting the hepatocyte growth factor-cMET axis in cancer therapy.

Authors:  George R Blumenschein; Gordon B Mills; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.